Background: Primary pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare subtype of non-small cell lung cancer (NSCLC). Nevertheless, no universally acknowledged standards of care have been reported to be effective and productive for the treatment of this tumor. Materials and Methods: A patient with advanced primary pulmonary LELC was treated by employing a combination of tislelizumab and chemotherapy. Results: The patient displayed a favorable response to the combination therapy. The tumor size exhibited conspicuous abatement in contrast to the pre-treatment baseline, and the tumor markers normalized. Conclusion: The combination of immunotherapy with chemotherapy appears to be more effective than therapy alone for managing advanced primary pulmonary LELC. On that account, further clinical trials are imperative to establish this combination regimen as a potential first-line treatment option for advanced cases.
References
[1]
Iezzoni, J.C., Gaffey, M.J. and Weiss, L.M. (1995) The Role of Epstein-Barr Virus in Lymphoepithelioma-Like Carcinomas. AmericanJournalofClinicalPathology, 103, 308-315. https://doi.org/10.1093/ajcp/103.3.308
[2]
Ho, J.C., Wong, M.P. and Lam, W.K. (2006) Lymphoepithelioma‐Like Carcinoma of the Lung. Respirology, 11, 539-545. https://doi.org/10.1111/j.1440-1843.2006.00910.x
[3]
Chen, B., Chen, X., Zhou, P., Yang, L., Ren, J., Yang, X., et al. (2019) Primary Pulmonary Lymphoepithelioma-Like Carcinoma: A Rare Type of Lung Cancer with a Favorable Outcome in Comparison to Squamous Carcinoma. RespiratoryResearch, 20, Article No. 262. https://doi.org/10.1186/s12931-019-1236-2
[4]
Bégin, L.R., Eskandari, J., Joncas, J. and Panasci, L. (1987) Epstein‐Barr Virus Related Lymphoepithelioma‐Like Carcinoma of Lung. JournalofSurgicalOncology, 36, 280-283. https://doi.org/10.1002/jso.2930360413
[5]
Chang, Y., Wu, C., Shih, J. and Lee, Y. (2002) New Aspects in Clinicopathologic and Oncogene Studies of 23 Pulmonary Lymphoepithelioma-Like Carcinomas. TheAmericanJournalofSurgicalPathology, 26, 715-723. https://doi.org/10.1097/00000478-200206000-00004
Qin, Y., Gao, G., Xie, X., Zhu, Z., Guan, W., Lin, X., et al. (2019) Clinical Features and Prognosis of Pulmonary Lymphoepithelioma-Like Carcinoma: Summary of Eighty-Five Cases. ClinicalLungCancer, 20, e329-e337. https://doi.org/10.1016/j.cllc.2018.12.014
[8]
Travis, W.D., Brambilla, E., Nicholson, A.G., Yatabe, Y., Austin, J.H.M., Beasley, M.B., et al. (2015) The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances since the 2004 Classification. JournalofThoracicOncology, 10, 1243-1260. https://doi.org/10.1097/jto.0000000000000630
[9]
Ma, H., Wu, Y., Lin, Y., Cai, Q., Ma, G. and Liang, Y. (2013) Computed Tomography Characteristics of Primary Pulmonary Lymphoepithelioma-Like Carcinoma in 41 Patients. EuropeanJournalofRadiology, 82, 1343-1346. https://doi.org/10.1016/j.ejrad.2013.02.006
[10]
Dong, A., Zhang, J., Wang, Y., Zhai, Z. and Zuo, C. (2015) FDG PET/CT in Primary Pulmonary Lymphoepithelioma-Like Carcinoma. ClinicalNuclearMedicine, 40, 134-137. https://doi.org/10.1097/rlu.0000000000000301
[11]
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., et al. (2018) Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. NewEnglandJournalofMedicine, 379, 2040-2051. https://doi.org/10.1056/nejmoa1810865
[12]
Nghiem, P.T., Bhatia, S., Lipson, E.J., Kudchadkar, R.R., Miller, N.J., Annamalai, L., et al. (2016) PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. NewEnglandJournalofMedicine, 374, 2542-2552. https://doi.org/10.1056/nejmoa1603702
[13]
Kueh, H.Y., Yui, M.A., Ng, K.K.H., Pease, S.S., Zhang, J.A., Damle, S.S., et al. (2016) Asynchronous Combinatorial Action of Four Regulatory Factors Activates Bcl11b for T Cell Commitment. NatureImmunology, 17, 956-965. https://doi.org/10.1038/ni.3514
[14]
Herbst, R.S., Soria, J., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., et al. (2014) Predictive Correlates of Response to the Anti-Pd-L1 Antibody MPDL3280A in Cancer Patients. Nature, 515, 563-567. https://doi.org/10.1038/nature14011
[15]
Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., et al. (2015) Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. NewEnglandJournalofMedicine, 372, 2018-2028. https://doi.org/10.1056/nejmoa1501824
[16]
Tang, Z., Fang, R., Tong, G., Liu, P., Ou, Z. and Tang, Y. (2020) Overcoming Resistance to Anti-PD-1 Immunotherapy in Lymphoepithelioma-Like Carcinoma: A Case Report and Review of the Literature. LungCancer, 146, 335-340. https://doi.org/10.1016/j.lungcan.2020.06.027
